Showing 19,921 - 19,940 results of 41,940 for search '(( 50 ((ng decrease) OR (((nn decrease) OR (a decrease)))) ) OR ( a point decrease ))', query time: 0.98s Refine Results
  1. 19921

    Image_1_A Label-Free Quantitative Proteomic Analysis of Mouse Neutrophil Extracellular Trap Formation Induced by Streptococcus suis or Phorbol Myristate Acetate (PMA).PDF by Xiaoping Wang (110673)

    Published 2018
    “…In the present study, we used a label-free quantitative proteomic analysis of mouse NET formation induced by S. suis or phorbol myristate acetate (PMA), a robust NET inducer. …”
  2. 19922

    Table_1_Water mass composition in Fram Strait determined from the combination of 129I and 236U: Changes between 2016, 2018, and 2019.xlsx by A.-M. Wefing (13749271)

    Published 2022
    “…The overall spatial distribution of <sup>236</sup>U and <sup>129</sup>I was similar among the three sampling years, but a decrease in concentration was observed in the upper water column of the EGC. …”
  3. 19923

    DataSheet_1_Water mass composition in Fram Strait determined from the combination of 129I and 236U: Changes between 2016, 2018, and 2019.pdf by A.-M. Wefing (13749271)

    Published 2022
    “…The overall spatial distribution of <sup>236</sup>U and <sup>129</sup>I was similar among the three sampling years, but a decrease in concentration was observed in the upper water column of the EGC. …”
  4. 19924

    Table 5_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.pdf by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  5. 19925

    Data_Sheet_1_Soil Microbial Composition and phoD Gene Abundance Are Sensitive to Phosphorus Level in a Long-Term Wheat-Maize Crop System.doc by Ming Lang (3757117)

    Published 2021
    “…The number of keystone taxa decreased from 10 to 3 OTUs under increasing P rates from 0 to 200 kg ha<sup>–1</sup>. …”
  6. 19926

    Table 1_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  7. 19927

    Table 3_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  8. 19928

    Table 4_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.pdf by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  9. 19929

    Table 2_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  10. 19930

    Image 2_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  11. 19931

    Image 3_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  12. 19932

    Image 1_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

    Published 2025
    “…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”
  13. 19933

    Targeting Ruminative Thinking in Adolescents at Risk for Depressive Relapse: Rumination-Focused Cognitive Behavior Therapy in a Pilot Randomized Controlled Trial with Resting State... by Rachel H. Jacobs (622107)

    Published 2016
    “…</p><p><b><i>Trial Registration</i>:</b> ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT01905267" target="_blank">NCT01905267</a></p></div>…”
  14. 19934

    Effect of trauma/HS without or with IL-6 treatment on cardiac apoptosis-related gene expression; impact of Stat3 inhibition on the IL-6 effect. by Jeffrey A. Alten (80715)

    Published 2008
    “…SBR50/IL-6/N (stippled bars). In panel B, the 196 apoptosis-related genes whose expression levels were changed in SBR50 vs. sham in the first microarray experiment were separated into those genes whose transcript levels were increased in SBR50 vs. sham (135 genes; left side of panel) and those whose transcript levels were decreased in SBR50 vs. sham (61 genes; right panel). …”
  15. 19935

    Table_1_Estrogen Protects Neurotransmission Transcriptome During Status Epilepticus.XLSX by Dumitru A. Iacobas (5423981)

    Published 2018
    “…<p>Women with epilepsy commonly have premature onset of menopause. The decrease in estrogen levels is associated with increased occurrence of neurodegenerative processes and cognitive decline. …”
  16. 19936

    Loss of protein stability in the absence of myotubularin-MTMR12 interactions. by Vandana A. Gupta (142475)

    Published 2013
    “…<p>(A) Knockdown of <i>mtmr12</i> resulted in a strong decrease of myotubularin protein in <i>mtmr12</i> morphant zebrafish at 3 dpf by western blotting. …”
  17. 19937

    <i>Rps6</i>-deficiency induces p53 and disrupts rRNA processing. by Sarah A. Comerford (3854917)

    Published 2023
    “…Original magnifications; a, d, e (x 125; scale bars, 50μ); b, c, f, g (x 250; scale bars, 25μ). …”
  18. 19938

    Zn<sup>2+</sup> is required for the enhancement of NMDAR fEPSPS which requires NR2B-containing NMDARs and activation of Src family kinases (SFK). by John A. Sullivan (6018725)

    Published 2018
    “…Sample traces for each treatment shown to right, before (dark traces) and 50 minutes after (light traces) drug application. …”
  19. 19939

    Association of symptoms and a low HRQOL with the risk of reaching the combined poor health outcome within the subsequent 6 months based on separate time-dependent Cox proportional... by Moniek C. M. de Goeij (546764)

    Published 2014
    “…<p>The HR with its 95% confidence interval (CI) represents the increased risk of reaching the combined poor health outcome (dialysis, transplantation, and death) within the subsequent 6 months in patients with the symptom compared to patients without the symptom present, the increased risk with each additional symptom, and the increased risk with every 3-point lower physical and mental summary score. A decrease of 3 score points is considered to be clinically relevant. …”
  20. 19940

    Participant flow (CONSORT diagram). by David J. Diemert (8135568)

    Published 2024
    “…Peak anti-<i>Na</i>-GST-1 IgG levels were observed between 2 and 4 weeks following the third dose, regardless of <i>Na</i>-GST-1 formulation. IgG levels decreased but remained significantly above baseline in all groups by day 290, at which point all participants (20 of 20 evaluable participants) still had detectable IgG. …”